Total thyroidectomy removes the entire thyroid gland. Partial, also called hemithyroidectomy or thyroid lobectomy, removes one lobe and leaves the other. For most thyroid cancers, total thyroidectomy is the standard. Partial is acceptable for small, low-risk papillary cancers under 1 cm confined to one lobe with no lymph node involvement. The decision comes down to tumour size, type, stage, and whether radioiodine is needed afterwards.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Total thyroidectomy is the standard for most thyroid cancers because it allows radioiodine to be used afterwards and removes any bilateral disease that imaging might have missed. Partial thyroidectomy works for carefully selected low-risk cases, but the criteria are strict. A patient who looks like a partial case on ultrasound sometimes turns out to need total once the pathology comes back, and then a second operation becomes the only option.”

Most thyroid cancer patients fall into this category.

• Tumours over 1 cm: The ATA guidelines recommend total thyroidectomy for papillary thyroid cancer over 1 cm. Larger tumours have higher recurrence risk and benefit from complete gland removal and radioiodine.
• Bilateral or multifocal disease: Papillary thyroid cancer is commonly multifocal. Leaving one lobe in place when disease may be present bilaterally increases recurrence risk sharply.
• Aggressive histology: Follicular cancer, Hurthle cell cancer, medullary thyroid cancer, poorly differentiated or anaplastic thyroid cancer. All of these need total thyroidectomy without exception.
• Radioiodine needed post-operatively: When radioiodine ablation or treatment is part of the plan, the entire gland must be gone first. Partial thyroidectomy makes radioiodine ineffective because the normal remaining lobe absorbs it all.

For patients choosing scarless thyroid surgery, robotic cancer surgery includes the RABIT technique, a robotic-assisted scarless thyroidectomy performed through the axilla with no incision on the neck.

• Medication trade-off: Total thyroidectomy means lifelong levothyroxine. One tablet a day. For most patients it’s well tolerated. Partial avoids this but only if the remaining lobe functions normally, which isn’t guaranteed.
• Recurrence monitoring: After total thyroidectomy, thyroglobulin becomes a precise tumour marker. Any detectable thyroglobulin means cancer is back. This clean marker doesn’t exist after partial.
• Second surgery reality: If a partial case turns out to need total, the second operation in a previously operated neck carries significantly higher complication risk. Recurrent laryngeal nerve and parathyroid injury rates rise sharply on re-operation.
• Partial for the right patient: Papillary microcarcinoma under 1 cm, single lobe, no lymph node involvement, low-risk histology, patient fully informed. This narrow group genuinely does well with lobectomy alone.

For a full picture of how thyroid cancer surgery achieves cure and what happens to surveillance afterwards, our blog on thyroid cancer surgery walks through the complete picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs total thyroidectomy, completion thyroidectomy, thyroid lobectomy and RABIT at high volume, invented the RABIT scarless robotic thyroidectomy technique himself, and integrates neck dissection into the primary surgical plan for every case where staging and pathology indicate it.

That surgical volume matters in thyroid cancer more than most cancers. The decision between total and partial thyroidectomy looks simple on paper. In the operating room, it depends on what the surgeon actually finds, and a surgeon who has done thousands of thyroid operations reads those intraoperative signals differently from one who does them occasionally. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Early stage cervical cancer can often be treated without removing the uterus. For very early disease, conisation or cone biopsy removes the cancerous tissue while the uterus stays completely intact. For slightly larger early tumours in women who want to preserve fertility, trachelectomy removes only the cervix while leaving the uterus in place. For locally advanced disease that doesn’t need surgery, chemoradiation is the standard treatment and the uterus isn’t removed at all. Hysterectomy becomes the standard option from stage IB2 upward or when the tumour exceeds certain size thresholds.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The first question many young women ask after a cervical cancer diagnosis is whether they’ll lose their uterus. For a significant number of them, the honest answer is no. Stage, tumour size, lymph node status and fertility wishes all go into that discussion. It’s not a yes or no question at diagnosis. It’s a conversation the tumour board has with each patient’s specific pathology in front of them.”

Stage and tumour size determine which options are on the table.

• Conisation for stage IA1: Very early superficial cancer confined to the cervix. A cone-shaped piece of cervical tissue is removed. Uterus stays. Pregnancy remains possible. Cure rates above 95 percent for this stage.
• Trachelectomy for stage IA2 to IB1: Removes the cervix, upper vagina and surrounding tissue while the uterus stays in place. For tumours under 2 cm in carefully selected patients. Fertility preserved. Second trimester pregnancy risk needs cervical cerclage.
• Chemoradiation for locally advanced disease: From stage IB3 onward, concurrent cisplatin-based chemotherapy with radiation replaces surgery as the primary treatment. The uterus isn’t removed. Ovarian function may be affected but the uterus remains.
• Simple hysterectomy for low-risk early disease: A 2024 NEJM trial confirmed simple hysterectomy equals radical hysterectomy in recurrence outcomes for low-risk stage IB1 tumours under 2 cm. Less tissue removed, fewer side effects, same cure rate.

For patients undergoing robotic-assisted radical trachelectomy or radical hysterectomy where minimally invasive surgery is indicated, robotic cancer surgery brings nerve-sparing precision and significantly faster recovery than open surgery.

Some situations make hysterectomy the safest and most appropriate path.

• Tumours over 2 cm at stage IB2: Larger tumours have a higher risk of parametrial spread and lymph node involvement. Radical hysterectomy with pelvic lymph node dissection is the standard surgical approach here.
• Completed family, no fertility concern: For women who have completed childbearing, radical hysterectomy offers definitive treatment and removes the risk of future cervical cancer in the remaining uterus.
• Radiation-resistant or recurrent disease: When cervical cancer recurs after primary chemoradiation, pelvic exenteration or radical hysterectomy may be the only curative surgical option left.
• Advanced local disease requiring surgery: Stage IVA disease involving the bladder or rectum may need exenteration surgery. The uterus is removed as part of a wider resection.

For more on how HPV vaccination prevents the cervical cancer that makes these decisions necessary in the first place, our blog on HPV vaccine cervical cancer covers the prevention picture in full.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic-assisted radical hysterectomy, radical trachelectomy, and fertility-sparing cervical surgery using minimally invasive techniques, and presents every cervical cancer case to the tumour board so the fertility conversation happens before any treatment decision is finalised.

That fertility-first discussion at the first consultation, not as an afterthought after the surgical plan is already set, is what gives young women with cervical cancer a realistic picture of what their options actually are. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

It can. But not often, and not permanently. Stage I disease on active surveillance has a recurrence rate of 15 to 20 percent. Add a single cycle of adjuvant chemo and that drops below 5. Most recurrences happen within the first two years. After five years without a sign? The risk is very small. And here’s the part most patients don’t know going in. Even when testicular cancer comes back, it usually still responds to treatment.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “The fear of recurrence after testicular cancer is understandable. But the honest answer? Even if it comes back, it’s usually curable. The tumour markers catch it early, weeks before any scan shows something. The surveillance schedule isn’t just monitoring. It’s the safety net. And it works.”

Stage, type, and what the pathology showed. All three matter.

• Stage I on surveillance: Around 15 to 20 percent of stage I non-seminoma patients on active surveillance relapse. Seminoma runs about the same. Not everyone. But enough that the follow up schedule isn’t optional.
• Adjuvant treatment cuts it sharply: One cycle of BEP for non-seminoma or one to two cycles of carboplatin for seminoma after surgery drops recurrence risk below 5 percent. A small trade-off for a lot of peace of mind.
• Lymph node involvement: Positive retroperitoneal nodes push this into stage II territory. Surveillance alone isn’t standard here. RPLND or chemotherapy gets added.
• Tumour biology details: Lymphovascular invasion, elevated AFP or beta-hCG, high embryonal carcinoma content. These findings in the pathology report push the team toward adjuvant treatment rather than just watching.

For patients whose surveillance or recurrence workup leads to a surgical reassessment of lymph nodes, robotic cancer surgery brings minimally invasive RPLND precision with faster recovery.

Markers first. Scans next. Chemotherapy when needed.

• Tumour markers drawn every visit: AFP and beta-hCG normalise after surgery. A rising number afterwards is the earliest warning. Weeks before anything shows on imaging. That’s why skipping the blood test isn’t an option.
• CT scan schedule: Chest, abdomen, pelvis every 3 to 4 months for the first two years. Then less often. The retroperitoneal lymph nodes are the most common place for relapse to appear first.
• BEP chemotherapy: Three to four cycles of bleomycin, etoposide and cisplatin. Highly effective even for advanced recurrent disease. Cure rates for relapsed testicular cancer sit above 70 percent.
• Second primary risk: The other testicle carries a 2 to 5 percent lifetime risk of a new cancer. Different from recurrence but equally important. Monthly self-examination and any new lump reported promptly.

For a full picture of testicular cancer from diagnosis through to treatment options, our blog on testicular cancer covers the complete picture.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs radical inguinal orchiectomy and minimally invasive RPLND for testicular cancer, guides post-surgical surveillance and adjuvant therapy decisions through the tumour board, and counsels patients on recurrence risk, follow up schedule and second primary monitoring. Every testicular cancer case is reviewed by the tumour board before the treatment plan is finalised.

That recurrence risk conversation at the first appointment, not as an afterthought weeks later, is what lets patients go into surveillance with a clear plan rather than ongoing anxiety. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

Resection is better when the liver behind the tumour is healthy enough to function after part of it is removed. Transplant is better when the liver itself is diseased, usually cirrhotic, and the tumour fits within the size and number criteria that make recurrence after a donated organ unlikely. Both can cure liver cancer. The tumour is rarely the only deciding factor. The liver’s own health decides as much as the cancer does.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Liver resection and transplant are not competing options. They’re answers to different clinical questions. Resection asks whether the tumour can be removed with enough healthy liver left behind. Transplant asks whether the cancer fits within criteria where recurrence after a donated organ is unlikely enough to justify using it. The tumour board weighs both before recommending either.”

Good liver function behind the tumour changes everything.

• Healthy underlying liver: Child-Pugh A function, no significant portal hypertension. The remnant liver regenerates. Patients with cirrhosis are at much higher risk for post-resection failure. That’s the key dividing line between who resects and who doesn’t.
• Resectable tumour anatomy: Single or limited tumours not hugging major vessels or bile ducts. Clear margins needed. At least 20 to 30 percent functional liver volume must remain after the resection.
• No donor, no waiting: Resection is available now. No list. No matching. No lifelong immunosuppression afterwards. For patients with good liver function and resectable disease, that’s a real practical advantage.
• Beyond Milan but still confined: Tumours too large for transplant criteria but still within the liver can be resected when function holds up. These patients don’t have a transplant path without downstaging first.

For patients whose liver cancer is removed using minimally invasive approaches, robotic cancer surgery brings precision hepatectomy with lower blood loss and faster recovery than open liver resection.

• Milan criteria define transplant eligibility: Single tumour under 5 cm, or up to three tumours none exceeding 3 cm, no vascular invasion, no spread outside the liver. Within these criteria 5-year post-transplant survival exceeds 70 percent.
• Recurrence after resection in cirrhotic liver: Runs 50 to 70 percent at 5 years. Not because surgery failed. The remaining diseased liver keeps generating new tumours. Transplant removes that substrate entirely.
• Downstaging for transplant: Patients outside Milan criteria can sometimes be brought inside using TACE or ablation before listing. Bridge therapy. Standard at experienced centres now, not a workaround.
• Living donor reality in India: Deceased donor availability is very limited here. Living donor liver transplant from a family member is the primary transplant pathway at most Indian centres. That changes the waiting time equation completely from what patients read about Western transplant programmes.

For patients who want to understand whether liver cancer is curable at their current stage, our blog on liver cancer curable explains what that means across stages and treatment types.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs robotic and laparoscopic hepatectomy for liver cancer resection, works closely with the liver transplant and hepatology teams for transplant assessment cases, and presents every liver cancer case to the tumour board so both resection and transplant are formally evaluated before any recommendation is made.

That joint evaluation at the first consultation, rather than being moved between departments after initial workup, is what prevents patients being funnelled into one pathway when the other might serve them better. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.

For locally advanced esophageal cancer, chemo isn’t just given before surgery. It’s given to make surgery possible. The standard approach for operable esophageal cancer is neoadjuvant chemoradiotherapy first, then esophagectomy 6 to 12 weeks later. Chemo shrinks the tumour, downgrades the stage, clears microscopic spread, and turns an operation that couldn’t be done safely into one that can. The operability question gets reassessed after chemo, not decided before it.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Neoadjuvant chemoradiotherapy before esophagectomy isn’t a delay in treatment. It is the treatment. We’re not waiting to see what happens. We’re actively shrinking the tumour, clearing the margins, improving the chances that the operation will achieve what we need it to achieve. The surgery after chemo is often a better, cleaner operation than surgery without it would have been.”

Several things shift during the neoadjuvant window. All of them matter.

• Tumour downstaging: Chemoradiotherapy shrinks the primary tumour and reduces lymph node involvement. A T3 tumour invading adjacent tissue can become a T2 confined to the oesophageal wall. That changes the operation entirely.
• Margin improvement: Smaller tumour means the surgeon has more room to achieve R0 resection, clear margins all round. Positive margins in oesophageal surgery are a major driver of recurrence.
• Pathological complete response: Around 25 to 30 percent of patients who complete neoadjuvant chemoradiotherapy show no remaining cancer on the surgical specimen. No viable cells at all. Surgery still usually goes ahead to confirm it.
• Fitness window: The 6 to 12 week gap between finishing chemoradiotherapy and operating also gives the patient time to recover nutritionally and physically. Oesophagectomy is a major operation. Going in stronger improves outcomes.

For patients whose oesophageal cancer requires minimally invasive resection, robotic cancer surgery brings thoracoscopic and laparoscopic precision to oesophagectomy, reducing blood loss and recovery time compared to open surgery.

Re-staging drives the decision. Several assessments run together.

• PET-CT re-staging: Shows metabolic activity in the tumour and lymph nodes after chemo. Significant reduction in uptake signals good response. Persistent high uptake raises the question of whether surgery is still the right next step.
• CT scan reassessment: Measures change in tumour size, local invasion and lymph node status. Compared directly against the pre-chemo staging scans to quantify response.
• Endoscopy and biopsy: Visual assessment of the oesophagus after chemoradiotherapy, with biopsies to check for residual cancer in the mucosa. Helps the surgeon plan the extent of resection.
• Patient fitness reassessment: Pulmonary function, nutritional status, weight, performance score all get reviewed before the surgical date is confirmed. Chemo takes a toll. Not everyone bounces back at the same rate.

For patients wanting to understand overall prognosis and what treatment response means for long-term outcomes, our blog on whether esophageal cancer curable covers the honest picture across stages.

Dr. Sandeep Nayak has spent 24 years in surgical oncology. He holds DNB qualifications in Surgical Oncology and General Surgery, plus a fellowship in Laparoscopic and Robotic Onco Surgery. He performs minimally invasive oesophagectomy using thoracoscopic and laparoscopic approaches, coordinates the neoadjuvant chemoradiotherapy plan with medical and radiation oncology, and re-stages every patient before confirming the surgical date. Every oesophageal cancer case goes through tumour board review before treatment begins.

That end-to-end coordination from neoadjuvant planning through to surgical recovery is what gives oesophageal cancer patients the best chance at an R0 resection and the strongest recovery from one of oncology’s most demanding operations. Call +91 8104310753 to book your consultation.

Disclaimer: This blog is for informational purposes only and is not a substitute for professional medical advice.